# Doxycycline in Type II Diabetes

> **NCT06329882** · PHASE1,PHASE2 · RECRUITING · sponsor: **Mostafa Bahaa** · enrollment: 60 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Sitagliptin 100mg
- **DRUG:** Doxycyclin

## Key facts

- **NCT ID:** NCT06329882
- **Lead sponsor:** Mostafa Bahaa
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-30
- **Primary completion:** 2026-03-20
- **Final completion:** 2026-04-20
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06329882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06329882, "Doxycycline in Type II Diabetes". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06329882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*